{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:52:34Z","timestamp":1791269554740,"version":"4.1.0"},"reference-count":13,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Continuous nucleos(t)ide analogue (NA) therapy for chronic hepatitis B (CHB) effectively maintains viral suppression but rarely results in functional cure. Finite NA therapy has been proposed to increase rates of HBsAg loss; however, international guidelines provide conflicting recommendations. This study compares the efficacy and safety of finite versus continuous NA therapy in HBeAg\u2010negative adults using randomized controlled trials. We included parallel\u2010group randomized controlled trials (RCTs) comparing nucleos(t)ide analogue (NA) cessation versus continuation in non\u2010cirrhotic, virally suppressed HBeAg\u2010negative adults. Two reviewers independently screened studies and assessed risk of bias using Cochrane RoB 2. Random\u2010effects Mantel\u2013Haenszel meta\u2010analyses with Hartung\u2013Knapp adjustment and Paule\u2013Mandel estimation were used to pool risk ratios (RRs) with 95% confidence intervals (CIs). Certainty of evidence was assessed using the GRADE approach. Four RCTs (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009357) met inclusion criteria. Discontinuation increased HBsAg loss vs. continuation (RR 5.02, 95% CI: 0.47\u201353.47;\n                    <jats:italic>I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200921.8%; low certainty), corresponding to ~53 additional losses per 1000 patients. However, finite therapy markedly increased virologic relapse (RR 23.09) and retreatment (RR 21.94) while reducing sustained off\u2010therapy virologic response (RR 0.46). Post\u2010cessation ALT flares were frequent but self\u2010limited or resolved with retreatment. No hepatic decompensation or serious adverse events occurred. In monitored, non\u2010cirrhotic adults, finite NA therapy may increase the probability of HBsAg loss despite predictable relapse and retreatment. With no evidence of severe harm, these findings support finite therapy as a selective, patient\u2010centered strategy toward functional cure in expert centers.\n                  <\/jats:p>","DOI":"10.1111\/jvh.70243","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:27:36Z","timestamp":1791268056000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Finite Versus Indefinite Nucleos(t)ide Analogue Therapy in\n                    <scp>HBeAg<\/scp>\n                    \u2011Negative Chronic Hepatitis B: Meta\u2011Analysis of Randomized Trials"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9441-8305","authenticated-orcid":false,"given":"Demver P.","family":"Gomez","sequence":"first","affiliation":[{"name":"Department of Internal Medicine De Los Santos Medical Center  Quezon City Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5374-3265","authenticated-orcid":false,"given":"Wilmyr F.","family":"Hababag","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine De Los Santos Medical Center  Quezon City Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"e_1_2_17_2_1","volume-title":"Hepatitis B","author":"World Health Organization","year":"2024"},{"key":"e_1_2_17_3_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl240023"},{"issue":"4","key":"e_1_2_17_4_1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL Guidance on Stopping Nucleos(t)ide Analogues in Chronic Hepatitis B Patients","volume":"15","author":"Kao J. H.","year":"2021","journal-title":"Hepatology International"},{"key":"e_1_2_17_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.018"},{"key":"e_1_2_17_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.14032"},{"issue":"5","key":"e_1_2_17_7_1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long\u2010Term Response After Stopping Tenofovir Disoproxil Fumarate in Non\u2010Cirrhotic HBeAg\u2010Negative Patients \u2013 FINITE Study","volume":"67","author":"Berg T.","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"12","key":"e_1_2_17_8_1","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited Sustained Response After Stopping Nucleos(t)ide Analogues in Patients With Chronic Hepatitis B: Results From a Randomised Controlled Trial (Toronto STOP Study)","volume":"68","author":"Liem K. S.","year":"2019","journal-title":"Gut"},{"issue":"2","key":"e_1_2_17_9_1","first-page":"277","article-title":"A Multicenter Randomized\u2010Controlled Trial of Nucleos(t)ide Analogue Discontinuation in HBeAg\u2010Negative Chronic Hepatitis B: The STOP\u2010NUC Trial","volume":"79","author":"van B\u00f6mmel F.","year":"2023","journal-title":"Journal of Hepatology"},{"key":"e_1_2_17_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.09.009"},{"issue":"4","key":"e_1_2_17_11_1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","article-title":"AASLD\/IDSA Practice Guideline on Treatment of Chronic Hepatitis B","volume":"83","author":"Ghany M. G.","year":"2026","journal-title":"Hepatology"},{"key":"e_1_2_17_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1075916"},{"key":"e_1_2_17_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16920"},{"key":"e_1_2_17_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.05.040"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.70243","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:27:43Z","timestamp":1791268063000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.70243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/jvh.70243"],"URL":"https:\/\/doi.org\/10.1111\/jvh.70243","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"2026-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70243"}}